MRK
Price
$84.06
Change
+$0.35 (+0.42%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
331.75B
19 days until earnings call
NVS
Price
$123.71
Change
+$0.77 (+0.63%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
197.93B
7 days until earnings call
Interact to see
Advertisement

MRK vs NVS

Header iconMRK vs NVS Comparison
Open Charts MRK vs NVSBanner chart's image
Merck & Co
Price$84.06
Change+$0.35 (+0.42%)
Volume$61.78K
Capitalization331.75B
Novartis AG
Price$123.71
Change+$0.77 (+0.63%)
Volume$16.68K
Capitalization197.93B
MRK vs NVS Comparison Chart in %
Loading...
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MRK vs. NVS commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRK is a StrongBuy and NVS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (MRK: $84.02 vs. NVS: $123.73)
Brand notoriety: MRK: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: MRK: 93% vs. NVS: 117%
Market capitalization -- MRK: $331.75B vs. NVS: $197.93B
MRK [@Pharmaceuticals: Major] is valued at $331.75B. NVS’s [@Pharmaceuticals: Major] market capitalization is $197.93B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MRK’s FA Score shows that 2 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • MRK’s FA Score: 2 green, 3 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than MRK.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MRK’s TA Score shows that 6 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).

  • MRK’s TA Score: 6 bullish, 3 bearish.
  • NVS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, MRK is a better buy in the short-term than NVS.

Price Growth

MRK (@Pharmaceuticals: Major) experienced а +3.82% price change this week, while NVS (@Pharmaceuticals: Major) price change was +1.50% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.39%. For the same industry, the average monthly price growth was +1.04%, and the average quarterly price growth was +11.01%.

Reported Earning Dates

MRK is expected to report earnings on Oct 30, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.39% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MRK($332B) has a higher market cap than NVS($198B). MRK has higher P/E ratio than NVS: MRK (935.64) vs NVS (23.38). NVS YTD gains are higher at: 31.728 vs. MRK (-13.958). NVS has higher annual earnings (EBITDA): 18.3B vs. MRK (6.91B). NVS has more cash in the bank: 14B vs. MRK (7.09B). NVS has less debt than MRK: NVS (26.3B) vs MRK (35.1B). MRK has higher revenues than NVS: MRK (60.1B) vs NVS (46.7B).
MRKNVSMRK / NVS
Capitalization332B198B168%
EBITDA6.91B18.3B38%
Gain YTD-13.95831.728-44%
P/E Ratio935.6423.384,001%
Revenue60.1B46.7B129%
Total Cash7.09B14B51%
Total Debt35.1B26.3B133%
FUNDAMENTALS RATINGS
MRK vs NVS: Fundamental Ratings
MRK
NVS
OUTLOOK RATING
1..100
2066
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
20
Undervalued
PROFIT vs RISK RATING
1..100
7013
SMR RATING
1..100
2429
PRICE GROWTH RATING
1..100
6246
P/E GROWTH RATING
1..100
10081
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRK's Valuation (13) in the Pharmaceuticals Major industry is in the same range as NVS (20). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.

NVS's Profit vs Risk Rating (13) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (70). This means that NVS’s stock grew somewhat faster than MRK’s over the last 12 months.

MRK's SMR Rating (24) in the Pharmaceuticals Major industry is in the same range as NVS (29). This means that MRK’s stock grew similarly to NVS’s over the last 12 months.

NVS's Price Growth Rating (46) in the Pharmaceuticals Major industry is in the same range as MRK (62). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.

NVS's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as MRK (100). This means that NVS’s stock grew similarly to MRK’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MRKNVS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
53%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
35%
Momentum
ODDS (%)
Bullish Trend 2 days ago
46%
Bullish Trend 2 days ago
49%
MACD
ODDS (%)
Bullish Trend 2 days ago
47%
Bullish Trend 2 days ago
56%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
49%
Bearish Trend 2 days ago
43%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
44%
Bullish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 2 days ago
48%
Bullish Trend 9 days ago
49%
Declines
ODDS (%)
Bearish Trend 4 days ago
50%
Bearish Trend 21 days ago
45%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
44%
Bearish Trend 2 days ago
43%
Aroon
ODDS (%)
Bullish Trend 2 days ago
54%
Bullish Trend 2 days ago
40%
View a ticker or compare two or three
Interact to see
Advertisement
MRK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IWS135.861.02
+0.76%
iShares Russell Mid-Cap Value ETF
IMCV77.900.53
+0.69%
iShares Morningstar Mid-Cap Value ETF
PBMY28.860.07
+0.26%
PGIM S&P 500 Buffer 20 ETF - May
BSL14.270.01
+0.07%
Blackstone Senior Floating Rate 2027 Term Fund
CORN17.39N/A
N/A
Teucrium Corn Fund

MRK and

Correlation & Price change

A.I.dvisor indicates that over the last year, MRK has been loosely correlated with PFE. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRK
1D Price
Change %
MRK100%
+0.37%
PFE - MRK
48%
Loosely correlated
+0.86%
AZN - MRK
44%
Loosely correlated
+1.40%
BIIB - MRK
44%
Loosely correlated
+1.74%
ABBV - MRK
43%
Loosely correlated
+2.30%
AMGN - MRK
40%
Loosely correlated
+1.30%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.64%
GSK - NVS
65%
Loosely correlated
+1.38%
AZN - NVS
63%
Loosely correlated
+1.40%
JNJ - NVS
55%
Loosely correlated
+0.90%
PFE - NVS
54%
Loosely correlated
+0.86%
AMGN - NVS
48%
Loosely correlated
+1.30%
More